Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK
Influenza and Other Respiratory Viruses · 2026
DOI: 10.1111/irv.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2026. Verfasst von Magda Bucholc und 5 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Agency, Belfast, UK. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Hospitalization, Vaccine Efficacy. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Agency.
Abstract (Originalsprache)
Background
Seasonal influenza causes substantial morbidity and hospitalisation each year. We estimated influenza vaccine effectiveness (VE) against laboratory‐confirmed influenza‐associated hospitalisation among patients in Northern Ireland (NI) during the 2024/25 influenza season.
Methods
We used a test‐negative design to estimate VE against hospitalisation. Influenza‐positive cases and test‐negative controls were identified through the national laboratory surveillance system and linked to hospital admission and vaccination records. VE was estimated by influenza type/subtype, age group, sex, vaccine type and time since vaccination.
Results
Among 15,133 hospitalised patients, 2024 (13.4%) tested positive for influenza. Among the 2024 patients admitted with laboratory‐confirmed influenza, the vast majority tested positive for influenza A ( n = 1803; 89.1%), whereas 221 cases (10.9%) were influenza B. Subtyping of influenza A identified 606 A(H1) infections and 93 A(H3) infections; the remaining 1104 influenza A samples were not subtyped. VE against laboratory‐confirmed influenza infection was 46.0% (95% CI: 39.7% to 51.8%), with higher VE in children aged 2–17 years (60.8%; 95% CI: 48.3% to 70.5%) than in adults aged 18–64 years (40.5%; 95% CI: 24.9% to 53.2%) and ≥ 65 years (42.3%; 95% CI: 33.2% to 50.1%). VE against influenza A across all ages was 41.4% (95% CI: 34.2% to 47.9%). Vaccination reduced the odds of hospitalisation due to influenza A(H1) by 44.3% (95% CI: 33.2% to 53.7%) and A(H3) by 49.9% (95% CI: 20.3% to 69.3%). VE against influenza B was higher at 76.4% (95% CI: 64.9% to 84.7%). For influenza A, VE was highest 2–8 weeks after vaccination at 51.9% (95% CI: 42.1% to 60.1%) and declined with time since vaccination to 44.6% (95% CI: 35.6% to 52.5%) at 9–16 weeks and 41.4% (95% CI: 15.4% to 60.1%) at ≥ 16 weeks. VE against influenza B remained high throughout the season. No statistically significant differences in VE by vaccine type were found.
Conclusions
Influenza vaccination reduced the risk of hospitalisation with laboratory‐confirmed influenza during the 2024/25 season, offering meaningful protection at individual and population levels, with the greatest benefit observed in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Agency, Belfast, UK.
- Centre for Public Health, Queen's University Belfast, Belfast, UK.
ORCID-Profile: Magda Bucholc, Siobhán Murphy, Emma Dickson, Declan T Bradley
Förderung
- Public Health Agency
Zitieren
APA
Bucholc, M., Murphy, S., O'Doherty, M. G., Wilton, S., Dickson, E., & Bradley, D. T. (2026). Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70303
Vancouver
Bucholc M, Murphy S, O'Doherty MG, Wilton S, Dickson E, Bradley DT. Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK. Influenza and Other Respiratory Viruses. 2026. doi:10.1111/irv.70303
BibTeX
@article{Bucholc2026,
author = {Bucholc, Magda and Murphy, Siobhán and O'Doherty, Mark G and Wilton, Suzanne and Dickson, Emma and Bradley, Declan T},
title = {Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK},
journal = {Influenza and Other Respiratory Viruses},
year = {2026},
doi = {10.1111/irv.70303}
}
EUVIMED